Azadeh Kheirolomoom
Overview
Explore the profile of Azadeh Kheirolomoom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kheirolomoom A, Kare A, Ingham E, Paulmurugan R, Robinson E, Baikoghli M, et al.
Biomaterials
. 2022 Jan;
281:121339.
PMID: 35078042
Ex vivo programming of T cells can be efficacious but is complex and expensive; therefore, the development of methods to transfect T cells in situ is important. We developed and...
2.
Zhang N, Foiret J, Kheirolomoom A, Liu P, Feng Y, Tumbale S, et al.
Adv Ther (Weinh)
. 2021 Oct;
4(9).
PMID: 34632048
Immunotherapy is an important cancer treatment strategy; nevertheless, the lack of robust immune cell infiltration in the tumor microenvironment remains a factor in limiting patient response rates. gene delivery protocols...
3.
Robinson E, Gowrishankar G, DSouza A, Kheirolomoom A, Haywood T, Hori S, et al.
J Control Release
. 2021 May;
335:281-289.
PMID: 34029631
Early cancer detection can dramatically increase treatment options and survival rates for patients, yet detection of early-stage tumors remains difficult. Here, we demonstrate a two-step strategy to detect and locate...
4.
Kakwere H, Zhang H, Ingham E, Nura-Raie M, Tumbale S, Allen R, et al.
Adv Healthc Mater
. 2021 Mar;
10(10):e2100008.
PMID: 33646600
Resiquimod is an immunopotent toll-like receptor 7/8 agonist with antitumor activity. Despite being potent against skin cancers, it is poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents...
5.
Fite B, Wang J, Kare A, Ilovitsh A, Chavez M, Ilovitsh T, et al.
Sci Rep
. 2021 Jan;
11(1):927.
PMID: 33441763
High intensity focused ultrasound (HIFU) rapidly and non-invasively destroys tumor tissue. Here, we sought to assess the immunomodulatory effects of MR-guided HIFU and its combination with the innate immune agonist...
6.
Zhang H, Tang W, Kheirolomoom A, Fite B, Wu B, Lau K, et al.
J Control Release
. 2020 Nov;
330:1080-1094.
PMID: 33189786
Resiquimod (R848) is a toll-like receptor 7 and 8 (TLR7/8) agonist with potent antitumor and immunostimulatory activity. However, systemic delivery of R848 is poorly tolerated because of its poor solubility...
7.
Ilovitsh T, Feng Y, Foiret J, Kheirolomoom A, Zhang H, Ingham E, et al.
Proc Natl Acad Sci U S A
. 2020 May;
117(23):12674-12685.
PMID: 32430322
Robust cytotoxic T cell infiltration has proven to be difficult to achieve in solid tumors. We set out to develop a flexible protocol to efficiently transfect tumor and stromal cells...
8.
Tucci S, Kheirolomoom A, Ingham E, Mahakian L, Tam S, Foiret J, et al.
J Control Release
. 2019 Jul;
309:277-288.
PMID: 31301340
Gemcitabine delivery to pancreatic ductal adenocarcinoma is limited by poor pharmacokinetics, dense fibrosis and hypo-vascularization. Activatable liposomes, with drug release resulting from local heating, enhance serum stability and circulation, and...
9.
Kheirolomoom A, Silvestrini M, Ingham E, Mahakian L, Tam S, Tumbale S, et al.
J Control Release
. 2019 Apr;
303:42-54.
PMID: 30978432
A successful chemotherapy-immunotherapy solid-tumor protocol should accomplish the following goals: debulk large tumors, release tumor antigen for cross-presentation and cross-priming, release cancer-suppressive cytokines and enhance anti-tumor immune cell populations. Thermally-activated...
10.
Tucci S, Seo J, Kakwere H, Kheirolomoom A, Ingham E, Mahakian L, et al.
Nanotheranostics
. 2018 Oct;
2(4):387-402.
PMID: 30324084
Squalenoylation of gemcitabine, a front-line therapy for pancreatic cancer, allows for improved cellular-level and system-wide drug delivery. The established methods to conjugate squalene to gemcitabine and to form nanoparticles (NPs)...